Abstract
Background: Tuberculosis (TB) remains a global health catastrophe. Mycobacterium w is a heat-killed immune-modulating vaccine designed to attenuate the effects of TB, reduce time to sputum conversion, and thereby decrease transmission and improve cure rates.
Objectives: To evaluate Mycobacterium w (M w) immunotherapy as an adjunct to chemotherapy in participants with pulmonary TB (PTB).
Search strategy: In January 2012, we performed both a database search, a handsearch and corresponded with experts in the field.
Selection criteria: Randomised and quasi-randomised controlled trials of M w immunotherapy versus placebo (or no control) for participants with PTB.
Data collection and analysis: Two of the authors (SP and ZK) independently extracted data. Dichotomous outcomes were analysed using risk ratios (RR) and 95% confidence intervals (CI).
Outcomes: The primary outcome was to determine the effect of M w therapy on sputum conversion. Secondary outcomes were to determine the frequency of adverse reactions.
Main Results: Three trials (four papers) involving 368 participants were included. All four papers had methodological flaws. Overall, 173 participants received M w and 168 participants received placebo or no control. M w immunotherapy was effective at reducing time to sputum conversion at days 15 (RR 2.31; 95% CI 1.75 to 3.06; P < 0.001) and 30 (RR 1.83; 95% CI 1.12 to 2.98; P = 0.02). After day 30, benefit was only demonstrated in the category II TB (re-treatment).
Conclusions: The meta-analysis suggests benefit as regards the time to sputum conversion. The available data on M w immunotherapy for participants with PTB are however methodologically flawed. We advise that M w be investigated in a well-structured, randomised controlled trial.
Keywords: Tuberculosis, Mycobacterium w, immunotherapy.
Current Pharmaceutical Design
Title:Mycobacterium w Immunotherapy for Treating Pulmonary Tuberculosis - a Systematic Review
Volume: 20 Issue: 39
Author(s): Shaheen Pandie, Mark E. Engel, Zita S. Kerbelker and Bongani M. Mayosi
Affiliation:
Keywords: Tuberculosis, Mycobacterium w, immunotherapy.
Abstract: Background: Tuberculosis (TB) remains a global health catastrophe. Mycobacterium w is a heat-killed immune-modulating vaccine designed to attenuate the effects of TB, reduce time to sputum conversion, and thereby decrease transmission and improve cure rates.
Objectives: To evaluate Mycobacterium w (M w) immunotherapy as an adjunct to chemotherapy in participants with pulmonary TB (PTB).
Search strategy: In January 2012, we performed both a database search, a handsearch and corresponded with experts in the field.
Selection criteria: Randomised and quasi-randomised controlled trials of M w immunotherapy versus placebo (or no control) for participants with PTB.
Data collection and analysis: Two of the authors (SP and ZK) independently extracted data. Dichotomous outcomes were analysed using risk ratios (RR) and 95% confidence intervals (CI).
Outcomes: The primary outcome was to determine the effect of M w therapy on sputum conversion. Secondary outcomes were to determine the frequency of adverse reactions.
Main Results: Three trials (four papers) involving 368 participants were included. All four papers had methodological flaws. Overall, 173 participants received M w and 168 participants received placebo or no control. M w immunotherapy was effective at reducing time to sputum conversion at days 15 (RR 2.31; 95% CI 1.75 to 3.06; P < 0.001) and 30 (RR 1.83; 95% CI 1.12 to 2.98; P = 0.02). After day 30, benefit was only demonstrated in the category II TB (re-treatment).
Conclusions: The meta-analysis suggests benefit as regards the time to sputum conversion. The available data on M w immunotherapy for participants with PTB are however methodologically flawed. We advise that M w be investigated in a well-structured, randomised controlled trial.
Export Options
About this article
Cite this article as:
Pandie Shaheen, Engel E. Mark, Kerbelker S. Zita and Mayosi M. Bongani, Mycobacterium w Immunotherapy for Treating Pulmonary Tuberculosis - a Systematic Review, Current Pharmaceutical Design 2014; 20 (39) . https://dx.doi.org/10.2174/1381612820666140905150215
DOI https://dx.doi.org/10.2174/1381612820666140905150215 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Food-derived bioactive peptides against chronic diseases
Chronic diseases, such as cardiovascular diseases and metabolic diseases, have become a great threat to the human health in recent decades due to the excessive food consumption and the prevalence of sedentary lifestyle. As a class of natural compounds, food-derived bioactive peptides have been demonstrated to possess great potential for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Coronavirus Disease (COVID-19): Features, Diagnosis, Treatments, and
Impacts
Coronaviruses Targeting Iron Acquisition by Mycobacterium tuberculosis
Infectious Disorders - Drug Targets Mucoadhesive Nanosystems for Nose-to-Brain Drug Delivery in the Treatment of Central Nervous System Diseases
Current Medicinal Chemistry SVM Prediction of Ligand-binding Sites in Bacterial Lipoproteins Employing Shape and Physio-chemical Descriptors
Protein & Peptide Letters Magnetic Materials for the Selective Analysis of Peptide and Protein Biomarkers
Current Medicinal Chemistry Pharmacogenomics – Implications in the Development of HIV-Associated Brain Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Role of Vitamin D in Prevention and Treatment of Infection
Inflammation & Allergy - Drug Targets (Discontinued) The Use of Propolis in Micro/Nanostructured Pharmaceutical Formulations
Recent Patents on Drug Delivery & Formulation Antimycobacterial Evaluation of Pyrazinoic Acid Reversible Derivatives
Current Pharmaceutical Design Synthesis, Antimycobacterial Activities and Phototoxic Evaluation of 5H-thiazolo[3,2-a]quinoline-4-carboxylic Acid Derivatives
Medicinal Chemistry Virtual Screening and Synthesis of Novel Antitubercular Agents Through Interaction-Based Pharmacophore and Molecular Docking Studies
Current Computer-Aided Drug Design Understanding the Role of Aldose Reductase in Ocular Inflammation
Current Molecular Medicine Induction of Cytochromes P450
Current Drug Metabolism Dendritic Cells in Pathogenesis of COPD
Current Pharmaceutical Design The Evolving Therapy of Rheumatic Diseases, The Future is Now
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Scanning the Genome of Mycobacterium tuberculosis to Identify Potential Lectins
Protein & Peptide Letters Editorial (Thematic Issue: Polypharmacology in Drug Discovery)
Current Pharmaceutical Design <I>In silico</I> Studies, Synthesis and Antitubercular Activity of Some Novel Quinoline - Azitidinone Derivatives
Current Computer-Aided Drug Design New Antifolate Inhibitors for Mycobacterium avium
Medicinal Chemistry Synthetic and Natural Monoamine Oxidase Inhibitors as Potential Lead Compounds for Effective Therapeutics
Central Nervous System Agents in Medicinal Chemistry